Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 12/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310292 | 0.79 | PDE3B (0.38) | PDE3BPDE3A | |
| SCHEMBL338324 | 0.76 | PDE3B (0.42) | PDE3BPDE3ACMA1 | |
| SCHEMBL31167649 | 0.75 | PSMB8 (0.36) | — | |
| SCHEMBL29320119 | 0.72 | TYRO3 (0.50) | PDE3BPDE3ACMA1 | |
| SCHEMBL28673518 | 0.69 | PDE3B (0.36) | PDE3BPDE3ACMA1MKNK1 | |
| SCHEMBL9038448 | 0.69 | PDE3B (0.42) | PDE3BPDE3ACMA1MKNK1 | |
| SCHEMBL18238489 | 0.68 | PDE3B (0.47) | PDE3BPDE3A | |
| SCHEMBL12232628 | 0.68 | PDE3B (0.54) | PDE3BPDE3A | |
| SCHEMBL341252 | 0.67 | PDE3B (0.49) | PDE3BPDE3A | |
| SCHEMBL8664696 | 0.65 | LIMK1 (0.39) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316886-B1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | SVENSSON CAMILLA (SE) | 2022-05-18 | — | — | EP | claimed |
| US-9161946-B2 | Dosing methods for treating disease | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | claimed |
| EP-3695837-B1 | A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR FOR TREATING HEPATITIS B | HOFFMANN LA ROCHE (CH) | 2024-11-20 | — | — | EP | disclosed |
| CN-112867725-B | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo [4,5-D ] pyrimidine modulators of CX3CR1 receptor and medical uses thereof | 坎塞拉有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-117241801-A | Inhibition of ubiquitin-specific protease 1 (USP 1) | 福马治疗有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3270915-B1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN LA ROCHE (CH) | 2020-04-15 | — | — | EP | disclosed |
| CN-102504001-B | 3, 5-disubstituted and 3,5, 7-trisubstituted-3H-oxazolo and 3H-thiazolo [4,5-d ] pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS INC | 2015-02-25 | — | — | CN | disclosed |
| CN-102504001-B | 3, 5-disubstituted and 3,5, 7-trisubstituted-3H-oxazolo and 3H-thiazolo [4,5-d ] pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS INC | 2015-02-25 | — | — | CN | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | ASTRAZENECA (SE) | 2007-06-21 | — | — | US | disclosed |
| WO-2006107257-A1 | NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| EP-1675862-A1 | NEW 2-SUBSTITUTED, 4-AMINO-THIAZOLO 4,5-D PYRIMIDINES, USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS, ESP. CX3CR1 | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006066080-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006066080-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005033115-A1 | NEW 2-SUBSTITUTED, 4-AMINO-THIAZOLO[4,5-D] PYRIMIDINES, USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS, ESP. CX3CR1 | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | HAVCR2, IFNG, TPMT | PDE3B 709/4885PDE3A 725/4885CMA1 2395/4885 |
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | CX3CR1, CCR2, CXCR4 | PDE3B 1043/4885PDE3A 1160/4885CMA1 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.